Compare · MTD vs TXG
MTD vs TXG
Side-by-side comparison of Mettler-Toledo International Inc. (MTD) and 10x Genomics Inc. (TXG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MTD and TXG operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- MTD is the larger of the two at $32.24B, about 3.4x TXG ($9.52B).
- Over the past year, MTD is up 20.4% and TXG is up 463.0% - TXG leads by 442.6 points.
- TXG has been more active in the news (9 items in the past 4 weeks vs 2 for MTD).
- Both have 25 recent analyst ratings on file.
- Company
- Mettler-Toledo International Inc.
- 10x Genomics Inc.
- Price
- $1630.22-0.58%
- $69.67-3.74%
- Market cap
- $32.24B
- $9.52B
- 1M return
- +15.60%
- -9.50%
- 1Y return
- +20.36%
- +462.99%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1997
- 2019
- News (4w)
- 2
- 9
- Recent ratings
- 25
- 25
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
10x Genomics Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Latest MTD
- Mettler-Toledo International Inc. to Host Investor Meeting
- Mettler-Toledo International Inc. to Host Third Quarter 2026 Earnings Conference Call
- UBS resumed coverage on Mettler-Toledo with a new price target
- Rothschild & Co Redburn initiated coverage on Mettler-Toledo with a new price target
- Director Shuman-Fabbri Natalia was granted 16 shares (SEC Form 4)
- RBC Capital Mkts initiated coverage on Mettler-Toledo with a new price target
- President and CEO Kaltenbach Patrick exercised 942 shares at a strike of $1,024.55 and sold $1,342,350 worth of shares (942 units at $1,425.00) (SEC Form 4)
- Director Salice Thomas P exercised 417 shares at a strike of $397.95 and sold $600,651 worth of shares (417 units at $1,440.41) (SEC Form 4)
- Director Salice Thomas P exercised 415 shares at a strike of $397.95 and sold $599,517 worth of shares (415 units at $1,444.62) (SEC Form 4)
- Head of Process Analytics Keller Gerry exercised 240 shares at a strike of $720.81 and sold $342,514 worth of shares (240 units at $1,427.14) (SEC Form 4)
Latest TXG
- 10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.
- 10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
- 10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
- 10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
- Argus initiated coverage on 10x Genomics with a new price target
- Director Suliman Shehnaaz sold $464,668 worth of shares (5,723 units at $81.19) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 23,792 units (SEC Form 4)
- Chief Executive Officer Saxonov Serge sold $2,030,562 worth of shares (25,000 units at $81.22) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,050,249 units (SEC Form 4)
- SEC Form 144 filed by 10x Genomics Inc.
- Chief Financial Officer Taich Adam sold $2,995,470 worth of shares (46,388 units at $64.57) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 316,344 units (SEC Form 4)